
Opinion|Videos|March 26, 2024
Perspectives on the Future on Myelofibrosis Treatment
Author(s)Stephen Oh, MD, PhD
Stephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.
Advertisement
Episodes in this series

Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)
Follow up and Clinical Workup at 3 Months:
- Exam: night sweats improved.
- Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
- Some spleen reduction.
- Patient receives ~1 unit RBC per month.
Follow up and Clinical Workup at 6 Months:
- Patient reports complaints of fatigue and abdominal pain.
- Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
- Patient now receives 2 units RBC per month.
- Experienced recurrence of SCC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















